The New Normal: What risk does Johnson & Johnson COVID-19 vaccine pose?
News 12's Elizabeth Hashagen was joined by Dr. Matthew Harris to talk about the new alert from the Food and Drug Administration regarding the Johnson & Johnson COVID-19 vaccine.
The FDA said its analysis had determined that the risk of thrombosis with thrombocytopenia syndrome after the administration of the shot warrants limiting of the authorization.
A new study suggests that Omicron BA.1 infections induce narrow immunity in people without vaccination, but when combined with vaccination it creates cross-immunity to other variants.
Three nasal spritzes now in advanced trials could trigger stronger immunity than shots in the arm - the location of the vaccines, which some scientists now want to change. There are eight nasal vaccines in clinical development now and three in phase 3 clinical trials, where they are being tested in large groups of people.
To block infections entirely, scientists want to deliver inoculations to the site where the virus first makes contact: the nose.